Towarzystwo Funduszy Inwestycyjnych PZU SA Boosts Stock Holdings in Intuitive Surgical, Inc. $ISRG

Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 59.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 37,597 shares of the medical equipment provider’s stock after purchasing an additional 14,043 shares during the quarter. Intuitive Surgical makes up about 4.0% of Towarzystwo Funduszy Inwestycyjnych PZU SA’s portfolio, making the stock its 6th largest holding. Towarzystwo Funduszy Inwestycyjnych PZU SA’s holdings in Intuitive Surgical were worth $16,815,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Intuitive Surgical in the 2nd quarter worth about $2,569,260,000. Rakuten Investment Management Inc. acquired a new position in Intuitive Surgical in the third quarter valued at approximately $388,436,000. Vanguard Group Inc. boosted its holdings in shares of Intuitive Surgical by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after buying an additional 670,302 shares in the last quarter. Sands Capital Management LLC grew its position in shares of Intuitive Surgical by 77.0% during the 3rd quarter. Sands Capital Management LLC now owns 1,341,109 shares of the medical equipment provider’s stock worth $599,784,000 after buying an additional 583,539 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Intuitive Surgical by 41.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,941,310 shares of the medical equipment provider’s stock valued at $868,212,000 after acquiring an additional 567,483 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Intuitive Surgical Trading Down 1.5%

NASDAQ ISRG opened at $472.16 on Friday. The business has a fifty day simple moving average of $513.26 and a 200 day simple moving average of $512.40. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $603.88. The firm has a market capitalization of $167.68 billion, a P/E ratio of 59.84, a PEG ratio of 3.70 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same period in the previous year, the firm earned $2.21 EPS. The business’s revenue for the quarter was up 18.8% compared to the same quarter last year. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, Director Gary S. Guthart sold 24,500 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total value of $12,987,450.00. Following the completion of the sale, the director directly owned 3,694 shares of the company’s stock, valued at approximately $1,958,189.40. This represents a 86.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Myriam Curet sold 421 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total transaction of $208,378.16. Following the completion of the sale, the executive vice president owned 409 shares of the company’s stock, valued at approximately $202,438.64. This trade represents a 50.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,407 shares of company stock valued at $17,534,067 in the last three months. 0.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ISRG. Sanford C. Bernstein lifted their price target on shares of Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. UBS Group set a $570.00 price target on Intuitive Surgical and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Wall Street Zen lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Piper Sandler reissued an “overweight” rating and issued a $620.00 price objective (up from $610.00) on shares of Intuitive Surgical in a research note on Friday, January 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $616.00 target price on shares of Intuitive Surgical in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $615.86.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.